Understanding Neonatal Abstinence Syndrome: Nursing Interventions

Sarah Saad E Althubyani [1], Maram Shanan Khazan Alenzi [2], Abdulraman Dhaher Hamad Albalawi [3], Hamdah Fadus Shabib Alruwili [4], Sultan Khalaf Gannam Alenazi [5], Dhahyah Nughaymish Shaman Alruwaili [6], Fatimah Mohammed Quwayan Alhazmi [7], Sharifah Fadhel R Alruwaili [8], Tahani Abdullah Ali Almanzalawi [9], Nadiah Ali Mohamad Daghriri [10]

1- Senior Specialist – Nursing, East Jeddah Hospital, Jeddah, Saudi Arabia
2- Nursing specialist, Al-Rabwa Health Center - Arar City, Saudi Arabia
3- Nursing technician, King Fahad Specialist Hospital, Tabuk, Saudi Arabia
4- Nursing technician, Al-Suwair General Hospital, Sakaka, Saudi Arabia
5- Nursing technician, Ministry of Health Branch- Northern Border Region, Saudi Arabia
6- Nursing technician, Alshalhoup Health Center, Sakaka, Al-Jouf, Kingdom of Saudi Arabia
7- Nursing technician, western Turaif primary Healthcare centar -Turaif, Saudi Arabia
8- Nursing technician, Al-Suwair General Hospital, Sakaka, Saudi Arabia
9- Nursing, Umm Lujj Al-Hawraa Hospital, Umm Lujj, Saudi Arabia
10- Nursing, Alserif Primary Health Care, Yanbu, Saudi Arabia

Abstract:

Neonatal Abstinence Syndrome (NAS) refers to a range of symptoms experienced by newborns exposed to drugs, particularly opioids, during pregnancy. Symptoms can manifest within the first few days of life and may include irritability, feeding difficulties, tremors, sweating, and seizures. Effective nursing interventions are crucial for managing NAS, focusing on both the immediate and long-term needs of the infant. Assessment of withdrawal symptoms is essential, followed by the implementation of a structured care plan that may include supportive measures such as swaddling, minimizing environmental stimuli, and promoting breastfeeding if appropriate. Additionally, regular monitoring of the infant's growth and development is vital for ensuring optimal outcomes. In cases where symptoms are severe, pharmacological interventions may be necessary. Nurses play a critical role in administering medications such as morphine or methadone to alleviate withdrawal symptoms and ensure the infant's comfort. Collaboration with a multidisciplinary team, including lactation consultants and social workers, is also important to address the family's needs and facilitate education regarding NAS. Providing emotional support and resources for parents whose infants are affected by NAS can significantly improve both maternal and child health outcomes. Education about the importance of follow-up care and ongoing support services must be emphasized to prevent potential long-term complications associated with substance exposure in utero.

Keywords: Neonatal Abstinence Syndrome (NAS), Nursing interventions, Drug exposure, Withdrawal symptoms, Swaddling, Environmental stimuli, Breastfeeding, Pharmacological treatment, Multidisciplinary team, Parental support, Follow-up care.

Introduction:

Neonatal Abstinence Syndrome (NAS) has emerged as a critical public health issue that commands the attention of healthcare professionals, particularly those in the nursing field. NAS refers to a spectrum of withdrawal symptoms experienced by infants exposed to addictive substances, primarily opioids, in utero. This condition is characterized by a variety of physical and neurological manifestations as the newborn transitions from a controlled intrauterine environment to the external world, where they are suddenly deprived of substances that their bodies have grown accustomed to. The complexity of NAS necessitates a thorough understanding of its pathophysiology, clinical presentation, and, importantly, effective nursing interventions that can mitigate its impact on neonates and their families [1].

Given the rising prevalence of opioid use and subsequent neonatal exposure, the importance of addressing NAS has escalated tremendously over the past two decades. The Centers for Disease Control and Prevention (CDC) reported that the incidence of NAS nearly quadrupled from 2000 to 2014, marking it as a significant concern across healthcare systems nationwide. This trend underscores the urgent need for improved nursing care strategies aimed at both immediate and long-term management of affected infants. As frontline healthcare providers, nurses play a vital role in identifying at-risk mothers, implementing evidence-based practices in neonatal care, and providing education and resources for families grappling with the challenges of NAS [2].

Research into NAS has identified a range of symptoms, including irritability, feeding difficulties, poor weight gain, seizures, and hypersensitivity to stimuli. These symptoms can manifest within 24 to 72 hours after birth, although some infants may not show signs until days or weeks later. The variability in presentation is influenced by several factors, including the type of substance used, the timing of exposure during pregnancy, and maternal factors such as co-occurring mental health conditions or socioeconomic challenges. Understanding these parameters is crucial for nurses as they assess and monitor infants suspected of having NAS [3].

Effective nursing interventions require a multifaceted approach that encompasses both acute care and long-term follow-up. Initially, nurses must engage in comprehensive assessments that involve utilizing standardized scoring systems, such as the Finnegan Neonatal Abstinence Scoring System, to evaluate the severity of withdrawal symptoms. This evidence-based tool helps to guide pharmacologic treatment when necessary, particularly in cases where non-pharmacologic interventions do not suffice. Such approaches may include strategies like swaddling, reducing environmental stimuli, promoting breastfeeding when possible, and facilitating parental involvement in caregiving. The incorporation of family-centered care principles further enhances outcomes by fostering a supportive environment for mothers and infants during this critical period [4].

Moreover, as the understanding of NAS evolves, the role of nurses expands beyond immediate clinical interventions. Education is paramount in addressing the underlying issues contributing to substance use and ensuring mothers have access to appropriate support systems, including counseling and addiction treatment resources. By integrating education into nursing practice, healthcare providers can empower families with knowledge about the implications of substance use during pregnancy and equip them with resources to support recovery and wellness. This proactive stance not only aids in reducing the incidence of NAS in future pregnancies but also promotes healthier family dynamics and community awareness regarding the complexities of addiction [5].

The growing body of literature on NAS also highlights the importance of interdisciplinary collaboration in optimizing care for affected infants. Nurses are integral to coordinating efforts among physicians, social workers, and addiction specialists, ensuring a comprehensive care plan that addresses both the immediate needs of the newborn and the broader psychosocial factors influencing maternal health. Effective communication and teamwork are essential in creating a continuum of care that provides stability for families navigating the challenges associated with NAS [6].

Epidemiology and Etiology of NAS:

Neonatal Abstinence Syndrome (NAS) is a condition seen in newborns that results from maternal substance use during pregnancy, particularly the use of opioids and other addictive substances. As a growing public health concern, NAS affects not only the individual infant but also the healthcare system and society at large. Understanding the epidemiology and etiology of NAS is crucial for developing effective prevention and intervention strategies [7].

NAS is a series of withdrawal symptoms experienced by infants who were exposed to drugs in utero. The onset of symptoms can occur within hours to weeks after birth, depending on the substance used and the duration of exposure. Common symptoms include irritability, excessive crying, poor feeding, vomiting, diarrhea, high-pitched crying, and seizures. These symptoms result from the infant's neurological and physiological

adaptations to the in utero presence of addictive substances [8].

The prevalence of NAS has increased significantly over the past two decades, reflecting broader societal trends regarding substance use, particularly opioid misuse. According to the Centers for Disease Control and Prevention (CDC), the incidence of NAS in the United States increased from 1.5 per 1,000 hospital births in 2000 to 8.0 per 1,000 births in 2012. This upward trend is attributed primarily to the opioid epidemic, which has led to higher rates of opioid prescriptions and, consequently, increased risks of dependence among pregnant women [8].

Geographically, the incidence of NAS varies widely. States hit hardest by the opioid crisis, such as West Virginia, Kentucky, and Ohio, report significantly higher rates of NAS compared to others. Moreover, demographic factors influence the likelihood of NAS; higher rates are observed among women with lower socioeconomic status, those living in rural areas, and certain racial and ethnic groups. Additionally, variations in state-level policies regarding substance use during pregnancy can impact the reported incidence of NAS, as some areas may have more robust screening and reporting procedures [9].

The economic burden of NAS is substantial. A study published in the journal "Pediatrics" estimated the cost associated with NAS, which includes hospital stays, long-term developmental support, and healthcare resources, to be in the billions of dollars annually. Increased awareness and attention to NAS have called into question the ethical, medical, and social implications of prenatal substance use, leading to a comprehensive examination of its antecedents [10].

Etiology of NAS

The etiology of NAS is multifaceted, involving various factors that contribute to both maternal substance use and its subsequent effect on the fetus. Key contributors to the development of NAS include:

1. **Maternal Substance Use:** Opioid misuse is the most significant risk factor for NAS, but other substances—such as benzodiazepines, alcohol, and stimulants—can also lead to withdrawal symptoms in neonates. The mechanism behind NAS largely involves the transfer of these substances across the placenta, which alters fetal neurological development and leads to dependency [11].
2. **Socioeconomic Factors:** Socioeconomic status is closely correlated with substance use during pregnancy. Women who experience poverty, lack access to healthcare, or have poor educational backgrounds are at increased risk of substance use and, consequently, giving birth to infants with NAS. These systemic factors create an environment where women may resort to drugs as a coping mechanism for stressors related to their circumstances [11].
3. **Mental Health Disorders:** Maternal mental health plays a critical role in substance use, as many women facing issues like depression, anxiety, or post-traumatic stress disorder may turn to drugs as a form of self-medication. The interplay between mental health and substance abuse creates a challenging scenario for healthcare providers, who must treat both the addiction and any underlying mental health concerns.
4. **Availability of Substance Abuse Treatment:** Access to effective treatment options for substance use disorders is crucial in preventing NAS. Women who can obtain help for their addictions during pregnancy show significant improvement in neonatal outcomes. In many cases, medically supervised tapering or the use of medication-assisted treatment (MAT) can mitigate the effects of opioid exposure during pregnancy and reduce the likelihood of NAS [12].

Implications for Prevention and Intervention

Given the rising prevalence of NAS, there is an urgent need for comprehensive public health strategies to address this issue. Effective interventions can be framed within the context of prevention, treatment, and support:

1. **Prevention Programs:** Public health education targeting pregnant women and healthcare providers regarding the risks associated with substance use during pregnancy is vital. Programs that emphasize the importance of prenatal care and substance abuse screenings can help identify at-risk individuals and provide them with the necessary support and resources [13].

2. **Medication-Assisted Treatment:** Expanding access to MAT for pregnant women addicted to opioids has proven effective in reducing the incidence of NAS. Ensuring that women have access to treatment before, during, and after pregnancy can mitigate the risks associated with neonatal withdrawal [13].

3. **Support Services:** Providing comprehensive support services, including mental health counseling and social services, can address the broader socioeconomic factors that contribute to substance use. Support for families postnatally is also crucial to ensure the healthy development of infants diagnosed with NAS.

4. **Longitudinal Care:** Infants diagnosed with NAS often require follow-up care to monitor their development and address any potential complications. Establishing multidisciplinary teams that include pediatricians, social workers, and developmental specialists can help ensure these children receive appropriate support throughout their early years [14].

Clinical Manifestations of NAS:

Neonatal Abstinence Syndrome (NAS) is a condition observed in newborns who have been exposed to certain drugs while in utero, most commonly opioids. As maternal substance use continues to be a public health issue, the incidence of NAS has risen significantly in recent years, leading to increased attention from healthcare providers, researchers, and policymakers. Understanding the clinical manifestations of NAS is essential for timely and appropriate intervention, management of affected infants, and, ultimately, the improvement of long-term outcomes for this vulnerable population [15].

Neonatal Abstinence Syndrome is characterized by a constellation of signs and symptoms that arise in a newborn following discontinuation of the drug exposure that the infant had received from the mother during pregnancy. The condition can affect babies exposed to various substances, including opioids, benzodiazepines, barbiturates, antidepressants, and alcohol, with opioid exposure being the most prevalent cause of NAS in the United States today. The underlying etiology involves the transplacental transfer of these substances, which alter the fetus's neurobiological development and lead to physical and behavioral withdrawal symptoms upon birth [16].

One of the defining characteristics of NAS is the timing of clinical manifestations, which can vary depending on the specific substance and the duration of maternal use. Opioid withdrawal symptoms typically manifest within 24 to 72 hours after birth, although in cases of long-acting opioids, such as methadone, signs may not appear until several days later. In contrast, infants born to mothers using short-acting opioids may present with symptoms much earlier. The period of observable symptoms is crucial for healthcare providers, as timely intervention is necessary to alleviate the risk of complications that can arise from untreated NAS [16].

Common Clinical Symptoms

Clinical manifestations of NAS can be broadly categorized into neurological, gastrointestinal, metabolic, and autonomic symptoms. The severity and type of symptoms can differ based on factors such as the extent of maternal drug use, the substance involved, and individual infant characteristics [17].

1. Neurological Manifestations:

Neurological symptoms are often among the most prominent features of NAS. They may include:

- **Irritability:** Infants may exhibit excessive crying, restlessness, and difficulty being soothed. This hyperirritability can be distressing for both the infant and caregivers [17].

- **Tremors:** Tremors, often described as "jitteriness," can be observed, particularly in the hands and feet. These can range from mild to severe and may be exacerbated when the infant is agitated.
- **Seizures:** A subset of infants may experience seizures, manifesting as rhythmic jerking movements or unresponsiveness, necessitating further medical evaluation and possible intervention.
- **Sleep Disturbances:** Infants may have difficulty maintaining a regular sleep-wake cycle, often experiencing fragmented sleep patterns or hypersomnolence [17].

2. Gastrointestinal Symptoms:

Gastrointestinal manifestations are also prevalent in infants diagnosed with NAS. These may include:

- **Feeding Difficulties:** Infants may struggle with feeding, characterized by poor appetite or difficulty latching onto the breast or bottle [18].
- **Vomiting:** Episodes of vomiting and regurgitation are not uncommon and may lead to weight loss and dehydration.
- **Diarrhea:** Frequent loose stools can contribute to the risk of dehydration and electrolyte imbalances [18].

3. Metabolic Derangements:

Metabolic symptoms may include:

- **Hypertonicity:** Infants may present with increased muscle tone, which can affect movement and feeding [19].
- **Dehydration and Electrolyte Imbalances:** Sweating or excessive crying may lead to dehydration, necessitating careful monitoring of fluid intake and output.

4. Autonomic Dysregulation:

Infants may exhibit signs of autonomic nervous system instability, including:

- **Temperature Instability:** NAS-affected infants may demonstrate difficulty maintaining a stable body temperature.
- **Respiratory Distress:** Alterations in respiratory patterns may arise, leading to episodes of apnea or tachypnea [20].

Diagnosis and Assessment

Diagnosing NAS requires a comprehensive assessment that includes a detailed maternal history, understanding the timing of drug exposure, and a physical examination of the neonate. Healthcare professionals commonly use standardized assessment scales, such as the Finnegan Neonatal Abstinence Scoring Tool, to systematically evaluate and quantify the severity of withdrawal symptoms. Using a scoring system enables clinicians to establish a baseline and modify treatment plans accordingly [21].

Management of NAS is multifaceted and may involve non-pharmacological and pharmacological interventions. Non-pharmacological approaches, often the first line of treatment, include creating a soothing environment, minimizing stimuli, and ensuring adequate feeding. Swaddling, promoting skin-to-skin contact, and quieting the environment can also help soothe the irritable infant [22].

In cases where non-pharmacological measures are insufficient, pharmacological treatment may be warranted. The most commonly used medications for treating NAS include morphine and methadone, which are employed to alleviate withdrawal symptoms and help stabilize the infant’s condition. Careful titration and monitoring of dosing are essential components of managed care to mitigate the risk of overdose or inadequate treatment.

The clinical manifestations of NAS can lead to significant concerns regarding long-term developmental outcomes. While many infants demonstrate a good prognosis with appropriate treatment, some evidence suggests that infants with more severe NAS may be at increased risk for developmental delays, behavioral issues, and challenges in school readiness as they grow older. Consequently, continued follow-up and supportive interventions such as developmental assessments and early intervention programs are critical in promoting optimal outcomes for these infants [23].

Assessment Tools and Diagnostic Criteria:

Neonatal Abstinence Syndrome (NAS) is a constellation of signs and symptoms resulting from withdrawal in neonates exposed to addictive substances during pregnancy, most commonly opioids. Its recognition and diagnosis are critical for ensuring timely and appropriate interventions that can significantly improve outcomes for the affected infants. The evaluation of NAS involves a variety of diagnostic tools and criteria that have evolved over time, reflecting advancements in medical understanding and training [24].

Understanding Neonatal Abstinence Syndrome

Before delving into evaluation and diagnosis, it is crucial to understand the pathophysiology of NAS. When a fetus is exposed to addictive substances in utero, it becomes dependent on those substances. Upon birth, the sudden cessation of drug exposure leads to withdrawal symptoms, which may manifest between 24 to 72 hours post-delivery. The clinical presentation of NAS can vary widely, encompassing gastrointestinal disturbances (such as vomiting and diarrhea), autonomic instability (including sweating and temperature dysregulation), neurological signs (like irritability, tremors, and seizures), and respiratory issues. The severity and duration of symptoms depend on various factors, including the drug type, dosage, duration of maternal use, and the gestational age of the neonate [25].

Diagnostic Criteria for NAS

The diagnosis of NAS is primarily clinical, relying on the identification of characteristic signs and symptoms. Some of the proposed diagnostic criteria involve the presence and severity of withdrawal symptoms, as well as a history of maternal substance use. The two most widely recognized scoring systems for diagnosing and assessing the severity of NAS are the Finnegan Neonatal Abstinence Scoring Tool and the Modified Neonatal Abstinence Score (MNAS) [26].

Finnegan Neonatal Abstinence Scoring Tool

Developed in the 1970s, the Finnegan tool is the most widely used assessment tool in the United States for diagnosing NAS. The scale evaluates withdrawal signs through a scoring system based on the presence and intensity of 21 different clinical signs, including:

- **Central Nervous System Signs**: Hypertonia, irritability, tremors, seizures.
- **Gastrointestinal Signs**: Poor feeding, vomiting, diarrhea [27].
- **Autonomic Signs**: Sweating, yawning, nasal stuffiness, sneezing.

Each sign is assigned a certain score based on its severity, with a higher cumulative score indicating a greater likelihood of NAS and the potential need for pharmacological interventions. A score over 8 is often used as a threshold for treatment initiation. The Finnegan scoring tool has been validated in multiple studies and remains a cornerstone in the assessment of NAS [27].

Modified Neonatal Abstinence Score (MNAS)

In recent years, an alternative scoring system, the Modified Neonatal Abstinence Score, has gained traction. Developed to enhance the sensitivity of NAS detection, MNAS incorporates scores for more clinical signs and symptoms, allowing for better differentiation between NAS and other neonatal conditions. Key modifications include:

1. Expansion of scoring categories with clearer definitions.
2. A comprehensive approach that takes into account not just the scoring of symptoms, but also their onset and duration.

Despite the enhanced precision offered by MNAS, the Finnegan Tool remains the standard due to its widespread familiarity and established clinical use [28].

Additional Evaluation Tools

In addition to scoring systems, several other evaluation tools aid in the diagnosis and management of NAS:

Maternal and Neonatal History

A detailed maternal history of substance use is vital for assessing the likelihood of NAS. Obstetrician and pediatrician collaboration leads to better outcomes. Specialized questionnaires can help identify maternal drug use during pregnancy, environmental factors, socioeconomic status, and mental health issues. Additionally, neonatal history should include factors such as birth weight,

gestational age, and any complications observed at birth [29].

Urine and Meconium Screening

Toxicology screening of maternal urine during pregnancy and newborn urine or meconium at birth can provide vital information regarding exposure to specific substances. While not used exclusively for diagnosis, the results can corroborate clinical assessments and inform treatment protocols. Meconium testing can identify exposure to drugs for a more extended period than urine testing and includes a wider array of substances [29].

Neurodevelopmental Assessments

Once NAS is diagnosed, continuous developmental monitoring becomes essential. Neurodevelopmental assessments can be conducted in follow-up visits to ensure timely identification of potential complications or long-term effects of withdrawal [30].

The Importance of Multi-Disciplinary Approach

NAS management often requires a multi-disciplinary approach involving neonatologists, pediatricians, nurses, social workers, and addiction specialists. The collaborative role of various healthcare providers ensures comprehensive care for the infants and their families. This cooperation often results in better evaluations, tailored treatment plans, and ultimately, improved infant outcomes. Extensive counseling and education provided to families about the implications of NAS are also critical elements of successful management [30].

Nursing Interventions for Managing Withdrawal Symptoms:

Withdrawal symptoms occur when an individual who has developed physical dependence on a substance, such as alcohol or drugs, abruptly reduces or stops their use. This phenomenon can manifest through a variety of physical, psychological, and emotional symptoms, which can range from mild to life-threatening. Effective management of withdrawal symptoms is critical in nursing care, as it not only supports the patient's physical health but also aids in their psychological well-being and their overall treatment journey [31].

Withdrawal symptoms vary depending on the substance involved, the duration of use, the dosage, and the individual's physiology. For example, withdrawal from alcohol can lead to symptoms such as tremors, agitation, anxiety, nausea, vomiting, seizures, and hallucinations. In contrast, opioid withdrawal may result in symptoms like muscle aches, diarrhea, vomiting, insomnia, and anxiety. Understanding these symptoms is paramount, as it allows nurses to anticipate potential complications and intervene early [32].

Nurses play a crucial role in the initial assessment and ongoing monitoring of individuals experiencing withdrawal. A thorough assessment involves obtaining a comprehensive history related to the substance use, including the type and duration of use, previous withdrawal experiences, comorbid conditions, and any psychiatric history. Standardized withdrawal assessment scales, such as the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) for alcohol withdrawal or the Clinical Opiate Withdrawal Scale (COWS) for opioid withdrawal, can guide nurses in quantifying the severity of withdrawal symptoms and tailoring interventions accordingly [33].

Continuous monitoring of vital signs, mental status, and fluid and electrolyte balance is also essential. Withdrawal symptoms can escalate quickly, resulting in complications such as delirium tremens in alcohol withdrawal or hyperthermia and infections from prolonged opioid withdrawal. Nurses should regularly assess for any change in the patient's condition and use objective measures to identify worsening symptoms that may require medical intervention.

Pharmacological approaches are often central to managing withdrawal symptoms. The choice of medication depends on the substance being withdrawn from and the specific symptoms exhibited by the patient [34].

For individuals withdrawing from alcohol, benzodiazepines are commonly prescribed to alleviate anxiety and prevent seizures. Dosing is often initiated at a higher level and tapered down based on ongoing assessments. Medications such as thiamine (Vitamin B1) are also given to prevent Wernicke's encephalopathy, a serious neurological condition associated with alcohol withdrawal.

Opioid withdrawal can be managed with medications such as Methadone or Buprenorphine,

which can alleviate symptoms without producing the euphoric effects associated with opioid use. Additionally, medications such as Clonidine may be prescribed to manage symptoms like anxiety and agitation [35].

Nurses must also educate patients regarding the pharmacological therapies being implemented, addressing any misconceptions about medications, and emphasizing the importance of adherence to the prescribed regimen. As some withdrawal symptoms can persist for extended periods, nurses should also prepare patients for the potential need for long-term pharmacological support, contributing positively to the overall recovery process [36].

Alongside pharmacological interventions, nurses should integrate non-pharmacological strategies to enhance patient comfort and promote recovery. Creating a calm, supportive environment is critical. Patients experiencing withdrawal may feel vulnerable and anxious, making it important for nursing staff to establish a therapeutic relationship characterized by empathy, respect, and trust.

Calming techniques such as deep breathing exercises, progressive muscle relaxation, and guided imagery can aid in reducing anxiety and discomfort. Ensuring the patient is in a safe environment where staff members are vigilant about potential complications can also alleviate fear and distress [36].

Providing adequate hydration and nutrition is vital, as withdrawal symptoms may lead to dehydration and malnutrition. Nurses should monitor fluid intake and offer easy-to-digest foods, ensuring that the patient receives a balanced diet. Additionally, maintaining a structured daily routine can help provide comfort and stability, which may be particularly beneficial for patients who exhibit heightened agitation or anxiety [37].

Education plays a pivotal role in the management of withdrawal symptoms. Nurses should provide patients and their families with information about the withdrawal process, addressing the physiological and psychological aspects of withdrawal. By demystifying the experience, patients may feel a greater sense of control and understanding regarding what they are experiencing.

Moreover, connecting patients with support systems is essential for long-term recovery. This may involve referring them to counseling services, support groups, or addiction specialists who can provide ongoing support after the initial withdrawal phase. Peer support can be particularly valuable, as it allows individuals undergoing withdrawal to connect with others who have experienced similar challenges, fostering a sense of community and shared understanding [37].

The management of withdrawal symptoms requires a collaborative, multidisciplinary approach. Nurses, physicians, pharmacists, and mental health professionals must work together to develop individualized care plans that address the complex needs of each patient. Regular team meetings can facilitate communication, allowing for adjustments to treatment plans based on the patient's progress [38].

Incorporating strategies from mental health professionals is particularly important, as withdrawal often co-occurs with mental health issues such as depression or anxiety disorders. By integrating psychological support with withdrawal management, the nursing team can address both the physical and emotional facets of addiction treatment [38].

Pharmacological Treatment Options:

Neonatal Abstinence Syndrome (NAS) is a withdrawal syndrome seen in newborns who were exposed to addictive substances, primarily opioids, during gestation. This condition affects an increasing number of infants worldwide as the rates of maternal substance use continue to rise. NAS can lead to a range of health issues, including low birth weight, seizures, irritability, feeding difficulties, and overall poor neonatal outcomes. Given its significant impact, understanding drug treatment options for NAS is critical for healthcare providers, caregivers, and families [39].

The pathophysiology of NAS involves the transfer of drugs from the mother to the fetus through the placenta, which exposes the developing fetus to the same substances the mother consumes. Opioid use during pregnancy can lead to physiological dependence in the fetus. Upon birth, the abrupt discontinuation of these substances leads to withdrawal symptoms, which may manifest within

24 to 72 hours post-delivery, depending on the type and timing of maternal drug use [39].

The presentation of NAS can vary widely between infants, but common symptoms include excessive crying, irritability, tremors, poor feeding, vomiting, diarrhea, and seizures. The severity of symptoms can range from mild to life-threatening, necessitating thorough monitoring and intervention. Healthcare providers typically use standardized assessment tools, such as the Finnegan Neonatal Abstinence Scoring System, to quantify symptom severity and guide treatment decisions [39].

Diagnosing NAS involves a comprehensive assessment that includes a detailed maternal history, physical examination of the infant, and possibly toxicology screening of urine or meconium. Identifying the specific substances involved is critical, as this information can impact both the severity of NAS and the approach to treatment [40].

Non-Pharmacological Management

Before jumping into pharmacological interventions, it is important to consider the non-pharmacological approaches to managing NAS. These methods focus on providing a supportive environment for the infant and may include:

1. **Swaddling**: Wrapping the baby in soft blankets to provide warmth and security.
2. **Dimmed Lighting and Reduced Noise**: Creating a calm environment to minimize overstimulation [40].
3. **Frequent Feeding**: Offering smaller, more frequent feedings to help manage gastrointestinal symptoms and promote weight gain.
4. **Soothing Techniques**: Using gentle rocking, breastfeeding, or skin-to-skin contact to help calm the infant.
5. **Minimizing Stress**: Creating a low-stress environment for the caregiver and the infant to foster an effective bonding process [40].

These non-pharmacological approaches are typically recommended as the first line of treatment, particularly for infants with mild to moderate symptoms [41].

Pharmacological Management

For more severe cases of NAS, pharmacological management may be necessary. The two primary medications used for the treatment of NAS are:

1. **Morphine**: This opioid agonist is frequently used for infants with more significant withdrawal symptoms. The goal of morphine therapy is to alleviate withdrawal symptoms and allow for a stable feeding pattern and improved weight gain. Dosages are typically initiated low and then gradually increased based on the infant's response and withdrawal scores. The aim is to provide a smooth transition until the infant can be safely tapered off the medication [41].
2. **Methadone**: In some cases, methadone may be used as an alternative treatment. Methadone has a longer half-life than morphine, which may provide a more stable level of opioids in the infant's system. This can help reduce the risk of withdrawal symptoms and improve overall stability during the treatment period [41].
3. **Buprenorphine**: This medication is a partial opioid agonist that can also be effective in managing NAS. It offers similar benefits to methadone but has a "ceiling effect," meaning higher doses do not produce increased effects beyond a certain point, which can make it a safer option for some infants [42].
4. **Phenobarbital**: Used primarily for cases of severe withdrawal characterized by seizures, phenobarbital is a barbiturate that helps to stabilize the central nervous system. This can be particularly useful for infants showing significant neuroexcitation, which may complicate withdrawal management [42].

Transitioning to Non-Opioid Options

As infants begin to respond to treatment, a gradual tapering of the pharmacological interventions will be necessary. The transition to non-opioid management is crucial to prevent the potential for dependency on these medications. Close monitoring

of symptoms continues during this process to ensure that withdrawal symptoms do not re-emerge [43].

The role of family members and caregivers in managing NAS cannot be overstated. Educating caregivers about the nature of NAS, its treatment options, and what to expect during the recovery process is vital for effective care. Support groups and counseling may also be beneficial for caregivers, providing them with resources and encouragement as they navigate the challenges of caring for an infant with NAS [43].

Support for Families and Caregivers:

Neonatal Abstinence Syndrome (NAS) is a group of conditions resulting from the withdrawal of a newborn from substances that were used by the mother during pregnancy. This phenomenon typically occurs in infants whose mothers consumed opioids, though substance use can range from alcohol and benzodiazepines to stimulants and other drugs. The rising prevalence of NAS has become a public health concern, compelling healthcare providers, policymakers, and social workers to focus attention on supporting both the affected infants and their families. Recognizing and addressing the challenges faced by caregivers of children with NAS is essential in facilitating proper care, ensuring healthy development, and promoting family cohesion [44].

NAS results in a range of symptoms in newborns, including irritability, seizures, feeding difficulties, poor weight gain, and gastrointestinal disturbances. The severity of NAS symptoms can vary significantly depending upon factors such as the type of substance used, the timing of the last use, and the duration of exposure during pregnancy. These challenges not only affect the infant but also reverberate through the family unit, putting substantial stress on parents and caregivers who often have to navigate complex healthcare systems, emotional upheaval, and societal stigma [45].

The implications of NAS extend beyond the immediate effects on the infant. Families often confront multifaceted issues such as economic strain, psychological stress, and social isolation. The caregiving role can be overwhelming, particularly when caregivers lack access to supportive resources. Therefore, it is crucial to develop strategies that support families in their caregiving roles to mitigate the adverse consequences of NAS [45].

The Importance of Support Systems

Effective support systems for families and caregivers of infants diagnosed with NAS can manifest through multiple strategies: healthcare services, community programs, educational resources, and caregiver networks. Each of these elements plays a vital role in fostering an environment conducive to healthy infant development and caregiver well-being [46].

1. Healthcare Services

Healthcare providers constitute the first line of support for families of infants with NAS. Comprehensive medical care is critical in managing withdrawal symptoms and monitoring the infant's growth and development. A multidisciplinary approach to treatment can enhance outcomes for infants and their families. Pediatricians, nurses, lactation consultants, and social workers should collaborate to create a holistic care plan that considers the physical, emotional, and social needs of both the infant and the caregivers [46].

Additionally, healthcare providers should ensure that they communicate effectively with families, offering clear explanations regarding treatment protocols and developmental expectations. Providing reassurance and guidance about managing NAS symptoms at home can empower caregivers and help reduce feelings of helplessness [46].

2. Community Programs

Community-based programs offering resources and support can significantly impact families coping with NAS. Many organizations focus on educating parents about NAS, offering them essential information and practical strategies for managing their child's care. These programs can include parenting classes, support groups, and workshops centered around infant care practices tailored to the unique needs of infants experiencing withdrawal [47].

Moreover, community organizations can facilitate connections among families facing similar challenges, promoting a sense of solidarity and reducing feelings of isolation. Peer support groups allow caregivers to share experiences, coping

strategies, and emotional support, creating a network of assistance that is vital for mental well-being [47].

3. Educational Resources

Education is paramount in supporting families impacted by NAS. Caregivers often experience confusion and anxiety surrounding their infant's diagnosis. Providing comprehensive educational resources equips them with knowledge about NAS, its symptoms, and expected recovery trajectories. Access to literature, brochures, and online content can help demystify the condition and empower caregivers to intervene through informed strategies.

Additionally, hospitals and clinics may offer discharge planning consultations that educate families on how to support their infant post-discharge. These resources should include information about recognizing potential withdrawal symptoms, fostering healthy feeding practices, and creating a safe environment for the infant's development [48].

4. Caregiver Networks

Building strong caregiver networks fosters resilience among families and aids in the overall success of the caregiving experience. These networks can comprise professionals from various fields, including social work and psychology, who can provide support for both practical caregiving strategies and emotional recovery. Additionally, connecting families with mental health services plays a critical role in addressing potential issues such as postpartum depression, anxiety, and substance use disorder among caregivers themselves.

Such networks can also engage with policymakers to advocate for family-centered services, increased funding for supportive resources, and access to mental health care. By mobilizing community support and fostering advocacy efforts, families can collaboratively work toward influencing policies that benefit children with NAS and their caregivers [49].

Addressing Societal Stigma

Stigmatization of families affected by NAS can exacerbate the emotional turmoil caregivers experience. Many families already feel judged for their circumstances, leading to fear of seeking help or voicing their struggles. Society must work to disengage stigma from substance use disorders and foster a more compassionate understanding of NAS [50].

Public awareness campaigns can reshape perceptions around NAS, emphasizing the importance of supportive interventions rather than punitive actions. Promoting conversations that humanize the issue and speak to the complexities of addiction and recovery allows for a more inclusive mindset regarding these vulnerable populations [51].

Long-term Outcomes and Follow-up Care:

Neonatal Abstinence Syndrome (NAS) is a withdrawal syndrome observed in infants who have been exposed to opioids and other addictive substances in utero. The condition is characterized by a range of symptoms including tremors, irritability, feeding difficulties, and seizures, which typically emerge within the first few days after birth. As the incidence of NAS has escalated due to the opioid epidemic, understanding the long-term outcomes and the importance of follow-up care for affected infants has become a critical area of inquiry in pediatric medicine [52].

Research has consistently shown that infants diagnosed with NAS are at risk for a number of long-term developmental challenges. While the immediate effects of withdrawal are well-documented, ongoing studies indicate that these infants may also experience cognitive, behavioral, and emotional difficulties later in childhood. According to longitudinal studies, children who were exposed to opioids in utero often exhibit lower IQ scores and academic challenges compared to their peers. These deficits are particularly concerning given the growing body of evidence suggesting that the severity and duration of withdrawal symptoms in NAS correlate with later cognitive outcomes [53].

Behavioral issues are another significant concern. Children with a history of NAS may manifest attention deficits, hyperactivity, and social integration problems as they grow older. These children are also at an increased risk of developing mood disorders, thereby necessitating early identification and intervention strategies. The

neurodevelopmental impact of in-utero substance exposure is complex and influenced by various factors including the type of substance used, maternal health and nutrition, and the presence of other co-occurring conditions [54].

In addition to cognitive and behavioral problems, research suggests that NAS-exposed children may face increased medical complications. This population experiences higher rates of hospital readmissions and may be more susceptible to chronic health issues such as respiratory disorders and failure to thrive. Consequently, early intervention and monitoring are imperative for promoting better health outcomes and ensuring that these infants transition more smoothly into childhood [55].

The importance of established follow-up care cannot be overstated for infants diagnosed with NAS. The goal of follow-up care is to monitor the child's growth, development, and overall health comprehensively. Multidisciplinary care models, which include pediatricians, neurologists, social workers, and mental health professionals, are recommended to address the multifaceted challenges faced by these children and their families [56].

One critical aspect of follow-up care is developmental screening. Regular assessments, typically conducted at pediatric visits, can help identify any emerging developmental delays. These screenings are generally conducted using validated tools such as the Ages and Stages Questionnaire (ASQ) and can be supplemented with referrals to early intervention programs when necessary. Experts recommend that developmental assessments begin at 2 months of age and continue at regular intervals through early childhood, particularly given the risk of delayed development in NAS-exposed infants [57].

Parent education and support are equally essential components of follow-up care. Due to the heightened anxiety, stress, and potential stigma related to parenting a child with a history of NAS, implementing interventions to support caregivers is vital. Training for parents on how to recognize and respond to their child's needs can be empowering and contribute to more positive outcomes. Support groups and parenting classes may also prove beneficial for enhancing parental skills and fostering social connections among families experiencing similar challenges [58].

Despite the robust recommendations for follow-up care, several barriers continue to impede the optimal management of infants with NAS. One significant challenge is the fragmentation of health services. In many areas, accessing multidisciplinary care can be difficult, leading to gaps in treatment and support. Moreover, the transition from hospital to home often poses risks, as some families may lack the resources or knowledge to navigate the healthcare system effectively [59].

In addition, external factors such as socioeconomic status, maternal mental health, and housing stability can profoundly influence the success of follow-up care. Families with limited financial resources may be less likely to adhere to ongoing appointments or interventions. Policymakers and healthcare providers must recognize and address these challenges to create more equitable healthcare access for all families affected by NAS [60].

Conclusion:

Understanding Neonatal Abstinence Syndrome (NAS) is crucial for healthcare professionals, particularly nurses, as they play a pivotal role in managing affected infants and supporting their families. The complexity of NAS, stemming from maternal substance use during pregnancy, necessitates a comprehensive approach that encompasses thorough assessment, timely interventions, and collaborative care. Effective nursing interventions, including symptom management, pharmacological treatments, and emotional support for families, are essential in promoting the health and well-being of neonates experiencing withdrawal.

Moreover, ongoing education and training for healthcare providers on NAS and its implications can enhance clinical outcomes and foster supportive environments for parents navigating the challenges of caring for an infant with NAS. By prioritizing individualized care plans and recognizing the importance of follow-up services, nurses can significantly impact the long-term developmental trajectories of these infants, ultimately improving their quality of life and reducing the risks associated with early substance exposure. Addressing NAS holistically not only aids in immediate management

but also contributes to healthier futures for both infants and their families, highlighting the critical role of nursing in this multifaceted issue.

References:

1. Welle-Strand GK, Skurtveit S, Jansson LM, et al. Breastfeeding among women in opioid maintenance treatment in Norway and its influence on neonatal abstinence syndrome. Acta Paediatr 2013;102:1060–6.
2. Jones HE, Heil SH, Tuten M, et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend 2013;131: 271–7.
3. Winkelman TNA, Villapiano N, Kozhimannil KB, et al. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004–2014. Pediatrics 2018;141(4) [pii:e20173520].
4. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 2012;307:1934–40.
5. Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ 2017;358:j3326.
6. Kaltenbach K, Holbrook AM, Coyle MG, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 2012;107(Suppl 1):45–52.
7. Villapiano NL, Winkelman TN, Kozhimannil KB, et al. Rural and urban differences in neonatal abstinence syndrome and maternal opioid use, 2004 to 2013. JAMA Pediatr 2017;171:194–6.
8. Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr 2012; 24:252–8.
9. Patrick SW, Davis MM, Lehmann CU, et al. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:650–5.
10. Hedegaard H, Warner M, Minino AM. Drug overdose deaths in the United States, 1999–2016. NCHS Data Brief 2017;294:1–8.
11. Loudin S, Murray S, Prunty L, et al. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. J Pediatr 2017;37:1108–11.
12. Ko JY, Patrick SW, Tong VT, et al. Incidence of neonatal abstinence syndrome - 28 States, 1999–2013. MMWR Morb Mortal Wkly Rep 2016;65:799–802.
13. Han B, Compton WM, Blanco C, et al. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. Ann Intern Med 2017;167:293–301.
14. Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008;199:396.e1–7.
15. Hudak ML, Tan RC, AAP The Committee on Drugs, Committee on fetus and newborn. Neonatal drug withdrawal. Pediatrics 2012;129(2):e540–60.
16. Wachman EM, Hayes MJ, Lester BM, et al. Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr 2014;165:472–8.
17. Guy GP, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697–704.
18. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med 2011;5:293–9.
19. Charles MK, Cooper WO, Jansson LM, et al. Male sex associated with increased risk for neonatal abstinence syndrome. Hosp Pediatr 2017;7:328–34.
20. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2012; 41:180–90.

21. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013;309:1821–7.
22. Velez M L, Jordan C J, Jansson L M. Reconceptualizing non-pharmacologic approaches to neonatal abstinence syndrome (NAS) and neonatal opioid withdrawal syndrome (NOWS): a theoretical and evidence-based approach. Neurotoxicol Teratol. 2021;88:107020.
23. Spence K, Boedeker R, Harhausen M, Kaushal G, Buchanan P, Josephsen J. Avoiding NICU transfers for newborns with neonatal opioid withdrawal syndrome (NOWS): a quality improvement initiative to manage NOWS on the mother-baby unit. J Addict Med. 2020;14(05):401–408.
24. Maruyama K, Shimoju R, Ohkubo M, Maruyama H, Kurosawa M. Tactile skin stimulation increases dopamine release in the nucleus accumbens in rats. J Physiol Sci. 2012;62(03):259–266.
25. Harder H J, Murphy A Z. Early life opioid exposure and potential long-term effects. Neurobiol Stress. 2019;10:100156.
26. Gellasch P, Johnson S, Walsh T A. The experiences and perceptions of neonatal clinicians when using a responsive bassinet. Adv Neonatal Care. 2023;23(04):E88–E95.
27. Boardman J P, Mactier H, Devlin L A. Opioids and the developing brain: time to rethink perinatal care for infants of opioid-dependent mothers. Arch Dis Child Fetal Neonatal Ed. 2022;107(01):98–104.
28. Kesavan K. Neurodevelopmental implications of neonatal pain and morphine exposure. Pediatr Ann. 2015;44(11):e260–e264.
29. Finnegan L P, Connaughton J F, Jr, Kron R E, Emich J P. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1-2):141–158.
30. Ryan G, Dooley J, Gerber Finn L, Kelly L. Nonpharmacological management of neonatal abstinence syndrome: a review of the literature. J Matern Fetal Neonatal Med. 2019;32(10):1735–1740.
31. Attarian S, Tran L C, Moore A, Stanton G, Meyer E, Moore R P. The neurodevelopmental impact of neonatal morphine administration. Brain Sci. 2014;4(02):321–334.
32. Oro A S, Dixon S D. Waterbed care of narcotic-exposed neonates. A useful adjunct to supportive care. Am J Dis Child. 1988;142(02):186–188.
33. Mangat A K, Schmölzer G M, Kraft W K. Pharmacological and non-pharmacological treatments for the neonatal abstinence syndrome (NAS). Semin Fetal Neonatal Med. 2019;24(02):133–141.
34. Van Puyvelde M, Gorissen A S, Pattyn N, McGlone F. Does touch matter? The impact of stroking versus non-stroking maternal touch on cardio-respiratory processes in mothers and infants. Physiol Behav. 2019;207:55–63.
35. Bloch-Salisbury E, Wilson J D, Rodriguez N et al. Efficacy of a vibrating crib mattress to reduce pharmacologic treatment in opioid-exposed newborns: a randomized clinical trial. JAMA Pediatr. 2023;177(07):665–674.
36. Patrick S W, Barfield W D, Poindexter B B. Neonatal Opioid Withdrawal Syndrome. Pediatrics. 2020;146(05):e2020029074.
37. Harvey K. New York: Bantam Books; 2015. The Happiest Baby on the Block: The New Way to Calm Crying and Help Your Newborn Baby Sleep Longer, 2nd ed.
38. Gao H, Gao H, Li M, Zhang H, Wang D, Wang B. Morphine use in the neonatal period and later neuropsychological development: a systematic review. Dev Med Child Neurol. 2021;63(01):22–28.
39. ACT NOW Collaborative. Young L W, Ounpraseuth S T, Merhar S L et al. Eat, sleep, console approach or usual care for neonatal opioid withdrawal. N Engl J Med. 2023;388(25):2326–2337.
40. Ardiel E L, Rankin C H. The importance of touch in development. Paediatr Child Health. 2010;15(03):153–156.
41. Harder H J, Murphy A Z. Early life opioid exposure and potential long-term effects. Neurobiol Stress. 2019;10:100156.
42. Bautista D M, Lumpkin E A. Perspectives on: information and coding in mammalian

sensory physiology: probing mammalian touch transduction. J Gen Physiol. 2011;138(3):291–301.
43. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468–2479.
44. Maalouf FI, Cooper WO, Slaughter JC et al. Outpatient pharmacotherapy for neonatal abstinence syndrome. J Pediatr. 2018;199:151–157.e1.
45. Nayeri F, Sheikh M, Kalani M et al. Phenobarbital versus morphine in the management of neonatal abstinence syndrome, a randomized control trial. BMC Pediatr. 2015;15:57.
46. Hall ES, Rice WR, Folger AT, Wexelblatt SL. Comparison of neonatal abstinence syndrome treatment with sublingual buprenorphine versus conventional opioids. Am J Perinatol. 2018;35(4):405–412.
47. Grossman MR, Lipshaw MJ, Osborn RR, Berkwitt AK. A novel approach to assessing infants with neonatal abstinence syndrome. Hosp Pediatr. 2018;8(1):1–6.
48. Slobiczek L, Hein DJ, Risoldi Cochrane Z, Gregory PJ. Morphine and methadone for neonatal abstinence syndrome: a systematic review. Neonatal Netw. 2018;37(6):365–371.
49. Tolia VN, Murthy K, Bennett MM et al. Morphine vs methadone treatment for infants with neonatal abstinence syndrome. J Pediatr. 2018;203:185–189.
50. Davis JM, Shenberger J, Terrin N et al. Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial. JAMA Pediatr. 2018;172(8):741–748.
51. Kraft WK, Gibson E, Dysart K et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008;122(3):e601–e607.
52. Winkelman TNA, Villapiano N, Kozhimannil KB et al. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004. Pediatrics. 2018;141(4):e20173520.
53. Streetz VN, Gildon BL, Thompson DF. Role of clonidine in neonatal abstinence syndrome: a systematic review. Ann Pharmacother. 2016;50(4):301–310.
54. Hudak ML, Tan RC, Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540–e560.
55. Surran B, Visintainer P, Chamberlain S et al. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol. 2013;33(12):954–959.
56. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006;26(1):15–17.
57. Lembeck AL, Tuttle D, Locke R et al. Outcome differences in neonates exposed in-utero to opioids managed in the NICU versus pediatric floor. J Addict Med. 2019;13(1):75–78.
58. Murphy K, Coo H, Warre R et al. Variations and similarities in clinical management of neonatal abstinence syndrome: findings of a Canadian survey. Paediatr Child Health. 2017;22(3):148–152.
59. Clemans-Cope L, Holla N, Lee HC et al. Neonatal abstinence syndrome management in California birth hospitals: results of a statewide survey. J Perinatol. 2020;40(3):463–472.
60. Xiao F, Yan K, Zhou W. Methadone versus morphine treatment outcomes in neonatal abstinence syndrome: a meta-analysis. J Paediatr Child Health. 2019;55(10):1177–1182.